Palatin Technologies: Positive Phase 2b Results and Strategic Growth Opportunities Justify Buy Rating

TipRanks01:45 · Ratings

Express News | Palatin Technologies Inc - Bremelanotide Well Tolerated With No Serious Adverse Events

BreakingsDec 19 20:30

Express News | Palatin Announces Positive Phase Iib Breakout Study Results in Patients With Type 2 Diabetic Nephropathy

BreakingsDec 19 20:30

Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients With Type 2 Diabetic Nephropathy

PR NewswireDec 19 20:30

Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds

PR NewswireDec 16 20:30

HC Wainwright & Co. Reiterates Buy on Palatin Techs, Maintains $17 Price Target

BenzingaNov 26 00:25 · Ratings